1
|
Usenko TS, Senkevich KA, Basharova KS, Bezrukova AI, Baydakova GV, Tyurin AA, Beletskaya MV, Kulabukhova DG, Grunina MN, Emelyanov AK, Miliukhina IV, Timofeeva AA, Zakharova EY, Pchelina SN. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease. Gene 2023; 882:147639. [PMID: 37473971 DOI: 10.1016/j.gene.2023.147639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 07/22/2023]
Abstract
Last data demonstrated that exonic variants of LRRK2 (p.G2019S, p.M1646T) may affect the catalytic activity of lysosomal enzyme glucocerebrosidase (GCase) probably through the phosphorylation of Rab10 protein. We aimed to evaluate an association of LRRK2 exonic variants previously associated with alteration of phosphorylation levels for Rab10Thr73 with PD risk in Russian population and analyze an impact of p.G2019S mutation and selected LRRK2 variants on lysosomal hydrolase activities. LRRK2 variants were determined by full sequencing of LRRK2 in 508 PD patients and 470 controls from Russian population. Activity of lysosomal enzymes (glucocerebrosidase (GCase), alpha-galactosidase A (GLA), acid sphingomyelinase (ASMase) and concentrations of their corresponded substrates (hexosylsphingosine (HexSph), globotriaosylsphingosine (LysoGb3), lysosphingomyelin (LysoSM), respectively) were estimated in 211 PD patients and 179 controls by liquid chromatography with tandem mass spectrometry (LC-MS-MS) in dry blood spots. p.M1646T and p.N2081D were associated with PD (OR = 2.33, CI 95%: 1.1215 to 4.8253, p = 0.023; OR = 1.89, 95%CI: 1.0727 to 3.3313, p = 0.028, respectively) in Russian population. An increased LysoGb3 concentration was found in p.G2019S and p.N2081D LRRK2 carriers among PD patients compared to both PD patients and controls (p.G2019S: p = 0.00086, p = 0.0004, respectively; p.N2081D: p = 0.012, p = 0.0076, respectively). A decreased ASMase activity in p.G2019S LRRK2 carriers among PD patients (p = 0.014) was demonstrated as well. Our study supported possible involvement of LRRK2 dysfunction in an alteration of sphingolipid metabolism in PD.
Collapse
Affiliation(s)
- T S Usenko
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia.
| | - K A Senkevich
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia; The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Neurology and neurosurgery, McGill University, Montréal, QC, Canada
| | - K S Basharova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - A I Bezrukova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - G V Baydakova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Research Center for Medical Genetics, Moscow, Russia
| | - A A Tyurin
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - M V Beletskaya
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - D G Kulabukhova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - M N Grunina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - A K Emelyanov
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - I V Miliukhina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia; Institute of the Human Brain of RAS, Saint-Petersburg, Russia
| | - A A Timofeeva
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - E Y Zakharova
- Research Center for Medical Genetics, Moscow, Russia
| | - S N Pchelina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| |
Collapse
|
2
|
Usenko TS, Senkevich KA, Bezrukova AI, Baydakova GV, Basharova KS, Zhuravlev AS, Gracheva EV, Kudrevatykh AV, Miliukhina IV, Krasakov IV, Khublarova LA, Fursova IV, Zakharov DV, Timofeeva AA, Irishina YA, Palchikova EI, Zalutskaya NM, Emelyanov AK, Zakharova EY, Pchelina SN. Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy. Mol Neurobiol 2022; 59:2277-2287. [PMID: 35066761 DOI: 10.1007/s12035-021-02688-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 12/08/2021] [Indexed: 11/28/2022]
Abstract
The synucleinopathies are a group of neurodegenerative diseases characterized by the oligomerization of alpha-synuclein protein in neurons or glial cells. Recent studies provide data that ceramide metabolism impairment may play a role in the pathogenesis of synucleinopathies due to its influence on alpha-synuclein accumulation. The aim of the current study was to assess changes in activities of enzymes involved in ceramide metabolism in patients with different synucleinopathies (Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)). The study enrolled 163 PD, 44 DLB, and 30 MSA patients as well as 159 controls. Glucocerebrosidase, alpha-galactosidase, acid sphingomyelinase enzyme activities, and concentrations of the corresponding substrates (hexosylsphingosine, globotriaosylsphingosine, lysosphingomyelin) were measured by liquid chromatography tandem-mass spectrometry in blood. Expression levels of GBA, GLA, and SMPD1 genes encoding glucoceresobridase, alpha-galactosidase, and acid sphingomyelinase enzymes, correspondently, were analyzed by real-time PCR with TaqMan assay in CD45 + blood cells. Increased hexosylsphingosine concentration was observed in DLB and MSA patients in comparison to PD and controls (p < 0.001) and it was associated with earlier age at onset (AAO) of DLB (p = 0.0008). SMPD1 expression was decreased in MSA compared to controls (p = 0.015). Acid sphingomyelinase activity was decreased in DLB, MSA patients compared to PD patients (p < 0.0001, p < 0.0001, respectively), and in MSA compared to controls (p < 0.0001). Lower acid sphingomyelinase activity was associated with earlier AAO of PD (p = 0.012). Our data support the role of lysosomal dysfunction in the pathogenesis of synucleinopathies, namely, the pronounced alterations of lysosomal activities involved in ceramide metabolism in patients with MSA and DLB.
Collapse
Affiliation(s)
- T S Usenko
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia. .,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia.
| | - K A Senkevich
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia.,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia
| | - A I Bezrukova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia
| | - G V Baydakova
- Research Center for Medical Genetics, Moskvorechie str. 1, Moscow, 115478, Russia
| | - K S Basharova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia
| | - A S Zhuravlev
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia
| | - E V Gracheva
- Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - A V Kudrevatykh
- Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - I V Miliukhina
- Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia.,Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - I V Krasakov
- The Nikiforov Russian Center of Emergency and Radiation Medicine, Optikov str. 54, 197082, St. Petersburg, Russia
| | - L A Khublarova
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - I V Fursova
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - D V Zakharov
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - A A Timofeeva
- Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia
| | - Y A Irishina
- Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - E I Palchikova
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - N M Zalutskaya
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - A K Emelyanov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia.,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia
| | - E Y Zakharova
- Research Center for Medical Genetics, Moskvorechie str. 1, Moscow, 115478, Russia
| | - S N Pchelina
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia.,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia.,Institute of Experimental Medicine, 12, Acad. Pavlov Str, 197376, Saint-Petersburg, Russia
| |
Collapse
|
3
|
Usenko TS, Bezrukova AI, Bogdanova DA, Kopytova AE, Senkevich KA, Gracheva EV, Timofeeva AA, Miliukhina IV, Zakharova EY, Emelyanov AK, Pchelina SN. Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia. Neurosci Lett 2021; 741:135509. [PMID: 33227372 DOI: 10.1016/j.neulet.2020.135509] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 11/11/2020] [Accepted: 11/15/2020] [Indexed: 01/01/2023]
Abstract
Lysosomal integral membrane protein-2 (LIMP-2), encoded by the SCARB2 gene, is the specific lysosomal receptor for glucocerebrosidase enzyme. Association between rs6812193 and rs68250047 of SCARB2 with PD has been shown in genetic studies, including large genome-wide association studies. The aim of the current study was to determine whether rs6812193 and rs8475 are associated with PD in Russia. rs6812193 and rs8475 were genotyped in a total of 604 PD patients (65 PD patients with positive (fPD) and 539 PD patients with negative family history (sPD)) and 413 controls and also in 17 patients with PD associated with GBA mutations (PD-GBA) and 18 asymptomatic GBA mutation carriers (GBA-Carriers). SCARB2 expression was measured by real-time PCR in CD45+ blood cells in part of individuals in the studied groups. No linkage disequilibrium was shown between rs6812193 and rs8475 in Russian population. Increased PD risk for TT variant of rs8475 (OR = 2.02; p < 0.001) was found in sPD patients but not in fPD. rs6812193 and rs8475 were not associated with age at onset (AAO) of PD. SCARB2 expression level was decreased in GBA-PD patients and GBA-Carriers compared to PD patients (padjusted = 0.02, padjusted = 0.003, respectively) and GBA-Carriers compared to controls (padjusted = 0.013) with no significant difference in PD patients and controls. SCARB2 expression was not modified with rs6812193 and rs8475. In conclusion, rs8475 was associated with PD status. rs6812193 and rs8475 are not genetic modifier of AAO of PD and do not influence on SCARB2 mRNA level in CD45+ blood cells in studied groups. SCARB2 expression could be modified with GBA mutations and is independent of PD status.
Collapse
Affiliation(s)
- T S Usenko
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia.
| | - A I Bezrukova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - D A Bogdanova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - A E Kopytova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - K A Senkevich
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
| | - E V Gracheva
- Institute of the Human Brain RAS, Saint-Petersburg, Russia
| | - A A Timofeeva
- Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
| | - I V Miliukhina
- Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia; Institute of the Human Brain RAS, Saint-Petersburg, Russia
| | - E Y Zakharova
- Research Center for Medical Genetics, Moscow, Russia
| | - A K Emelyanov
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
| | - S N Pchelina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia; Institute of Experimental Medicine, Saint-Petersburg, Russia
| |
Collapse
|